Retre-Gel Shortage Update: What Patients Need to Know in 2026

Retre-Gel (benzocaine topical gel 20%) is a professional dental anesthetic that patients and providers sometimes struggle to locate. While the product is not currently on the FDA's official drug shortage list, there are real and documented reasons why access can be inconsistent. This article covers the current shortage status, historical context, FDA regulatory actions, and what patients can do right now.

Current FDA Shortage Status for Retre-Gel (2026)

As of 2026, the FDA's Drug Shortage Database does not list Retre-Gel or benzocaine topical gel as being in an active shortage. This means major manufacturing disruptions have not been officially reported to the FDA. However, patients and providers continue to report localized availability problems — particularly for professional-use dental gel formulations in specific regions.

Why Have Benzocaine Products Become Harder to Find?

Even without a formal FDA shortage declaration, several developments have tightened benzocaine availability over the past several years:

2018 FDA Safety Communication on Methemoglobinemia. The FDA urged manufacturers to stop marketing OTC oral benzocaine products for teething in infants and children under 2. Several manufacturers voluntarily pulled or reformulated products, reducing the total variety of benzocaine products on the market.

Benzene contamination recalls of 20% spray formulations have led some distributors to temporarily reduce overall benzocaine inventory as products are tested and reformulated.

Distribution channel fragmentation: Retre-Gel and professional benzocaine gels are sold through dental supply networks rather than retail pharmacy chains, creating geographic gaps.

Consolidation among dental supply distributors has reduced the number of companies competing to stock specialty dental products in all regions.

Historical Context: What Has Changed Since 2018?

In 2018, the FDA issued its most significant warning about benzocaine products — a safety communication linking over 400 reported cases of methemoglobinemia to benzocaine since 1971. More than 75% of cases involved life-threatening or serious outcomes, and 7 resulted in death. This prompted the FDA to mandate methemoglobinemia warning labels on all benzocaine products and push manufacturers to stop marketing OTC teething products for children under 2.

These regulatory actions changed the retail landscape. Fewer benzocaine product lines are marketed to consumers today than in 2015, but professional dental-use products like Retre-Gel, Hurricaine, and Benzo-Jel remain available through appropriate channels.

Are There Any Active Recalls on Retre-Gel?

As of 2026, there are no active FDA recalls specifically affecting Retre-Gel gel formulations. Spray formulations of 20% benzocaine from various manufacturers have been subject to recalls related to benzene contamination, but these have not affected Retre-Gel gel products. Always check FDA.gov for the most current recall information.

39,483+ patients found their medications in stock

39K+

Find Retre-Gel In Stock Today →

What Should Patients Do If They Can't Find Retre-Gel?

Ask for a functionally equivalent product. Hurricaine Gel, Benzo-Jel, and Orajel Maximum Strength contain 20% benzocaine and are clinically interchangeable with Retre-Gel for most applications.

Use medfinder to check nearby pharmacies. medfinder calls pharmacies in your area to verify stock, then texts you the results — saving you the time of calling around yourself.

Contact dental supply distributors. Companies like Henry Schein Dental, Patterson Dental, and Darby Dental supply professional benzocaine products directly and may be a more reliable source than retail pharmacies.

Ask your dentist. If your dentist uses benzocaine topical gel, they likely have a reliable supplier and may be able to advise on where to obtain it or recommend an equivalent product.

Consider non-benzocaine alternatives. If benzocaine products are genuinely unavailable, lidocaine-based topical anesthetics are effective alternatives. See our full guide on alternatives to Retre-Gel for details.

Bottom Line for Patients in 2026

Retre-Gel is not in a formal FDA shortage in 2026, but its dental-channel distribution model means it can be hard to locate through standard pharmacy channels. Equivalent 20% benzocaine gels remain broadly available. The key is knowing which alternatives to ask for and where to look — which is exactly what this guide is designed to help with.